AN2 Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022
Market Capitalization	83	609	185
Market Cap Growth	-49.48%	229.57%	-
Enterprise Value	-31	502	89
PE Ratio	-	-9.41	-4.32
PB Ratio	0.75	4.89	1.94
P/FCF Ratio	-1.63	-11.44	-5.53
P/OCF Ratio	-1.63	-11.44	-5.53
EV/EBITDA Ratio	0.26	-7.76	-2.17
EV/EBIT Ratio	0.26	-7.76	-2.17
EV/FCF Ratio	0.29	-9.42	-2.66
Debt / Equity Ratio	-	-	0.00
Debt / EBITDA Ratio	-	-	0.00
Debt / FCF Ratio	-	-	0.00
Quick Ratio	10.71	7.64	13.37
Current Ratio	10.91	7.87	13.72
Return on Equity (ROE)	-57.20%	-59.70%	-39.60%
Return on Assets (ROA)	-51.50%	-53.70%	-37.80%
Return on Capital (ROIC)	-65.00%	-55.84%	-44.29%
Earnings Yield	-79.34%	-10.62%	-23.13%
FCF Yield	-71.24%	-8.74%	-18.10%
Buyback Yield / Dilution	-53.53%	-53.85%	-481.46%
Total Shareholder Return	-53.53%	-53.85%	-481.46%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).